Who owns Lyell Immunopharma, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of LYEL from SEC Form 13F filings across 86 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-06-30 reporting period, 86 institutions disclosed 12.0M shares of Lyell Immunopharma, Inc. worth $168.2M — about 51.3% of shares outstanding; the largest disclosed holder is ARCH Venture Management, LLC. Source: SEC Form 13F filings, parsed by EvidInvest.
86
13F holders
$168.2M
value, 2026 filers
51.3%
of shares outstanding (12.0M sh)
23
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30 · % of fund = share of the manager's own book · % of co. = share of LYEL's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | ARCH Venture Management, LLC | 3.2M | $45.5M | 4.1% | 13.9% | 0.0% |
| 2 | GSK plc | 1.5M | $21.3M | 3.5% | 6.5% | 0.0% |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 786,774 | $11.1M | 0.0% | 3.4% | +9.6% |
| 4 | Orland Properties Ltd | 754,698 | $10.6M | 5.2% | 3.2% | 0.0% |
| 5 | BlackRock, Inc. | 724,342 | $10.2M | 0.0% | 3.1% | +277.6% |
| 6 | Almitas Capital LLC | 581,407 | $8.2M | 2.0% | 2.5% | +0.6% |
| 7 | Foresite Capital Management V, LLC | 476,386 | $6.7M | 1.8% | 2% | -0.1% |
| 8 | MILLENNIUM MANAGEMENT LLC | 367,473 | $5.2M | 0.0% | 1.6% | -19.9% |
| 9 | Opaleye Management Inc. | 344,025 | $4.8M | 0.4% | 1.5% | +334.9% |
| 10 | venBio Partners LLC | 337,697 | $4.7M | 0.9% | 1.4% | 0.0% |
| 11 | GEODE CAPITAL MANAGEMENT, LLC | 310,636 | $4.4M | 0.0% | 1.3% | +86.0% |
| 12 | Alphabet Inc. | 293,256 | $4.1M | 0.0% | 1.3% | 0.0% |
| 13 | STATE STREET CORP | 185,322 | $2.6M | 0.0% | 0.8% | +155.5% |
| 14 | HSG Holding Ltd | 152,299 | $2.1M | 0.2% | 0.7% | 0.0% |
| 15 | RENAISSANCE TECHNOLOGIES LLC | 130,190 | $1.8M | 0.0% | 0.6% | +11.8% |
| 16 | NORTHERN TRUST CORP | 118,500 | $1.7M | 0.0% | 0.5% | +291.3% |
| 17 | Qube Research & Technologies Ltd | 110,531 | $1.6M | 0.0% | 0.5% | +100.6% |
| 18 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 107,570 | $1.5M | 0.0% | 0.5% | +25.1% |
| 19 | MARSHALL WACE, LLP | 106,300 | $1.5M | 0.0% | 0.5% | -28.4% |
| 20 | Velan Capital Investment Management LP | 105,000 | $1.5M | 0.9% | 0.4% | +2.9% |
| 21 | VANGUARD FIDUCIARY TRUST CO | 93,095 | $1.3M | 0.0% | 0.4% | +7.1% |
| 22 | VANGUARD PORTFOLIO MANAGEMENT LLC | 91,891 | $1.3M | 0.0% | 0.4% | +299.3% |
| 23 | MIC Capital Management UK LLP | 87,028 | $1.2M | 0.3% | 0.4% | 0.0% |
| 24 | GOLDMAN SACHS GROUP INC | 86,779 | $1.2M | 0.0% | 0.4% | -24.2% |
| 25 | DIMENSIONAL FUND ADVISORS LP | 68,315 | $957,066 | 0.0% | 0.3% | +42.7% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.